Jan 16, 2019 -
Dec 05, 2018 - Shares have risen by just 5% since my initial article and lost a quarter of their value since my last update.I provide a recap of the bullish thesis and recent events.SAKURA phase 3 open-label data wa
Nov 01, 2018 - Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Jeanie Herbert - Senior Director of IR & Corporate Communications Daniel Browne - Co
Sep 10, 2018 - Revance is a clinical-stage biotechnology company focused on the development and commercialization of botulinum toxin (Botox) products for cosmetic and therapeutic applications.Near-term catalysts inc
Jul 17, 2018 - Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Jul 16, 2018 - Allergan is under pressure from activist shareholders and other investors to formulate a clear strategic plan and make more drastic changes to the company.Botox Aesthetics, Botox Migraine, and Restasi
May 30, 2018 - Revance Therapeutics (RVNC) announced Tuesday morning that Lauren Silvernail has resigned as its Chief Financial Officer and Chief Business Officer.
May 27, 2018 - AcelRx announces FDA acceptance of NDA for DSUVIA.BioMarin’s Palynziq receives FDA approval.Genmab ofatumumab flunks late-stage NHL study.
May 23, 2018 - The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this event.
May 14, 2018 - AGN is seeking strategic options to boost shareholder value.It may try to sell parts of AGN before LOE for Restasis or competition for Botox materializes.If investors buy this new narrative it could r